Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
- Written by PR Newswire Asia - Daily Bulletin Au RSS
![]() |
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for TLX66 (90Y-besilesomab), for conditioning treatment prior to hematopoietic stem cell...
Read more: Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment